Scarica l'app Stockscreener
172.00
0.77%
-1.33
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DHR Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$173.33
Aprire:
$173.54
Volume 24 ore:
2.99M
Relative Volume:
0.68
Capitalizzazione di mercato:
$121.74B
Reddito:
$24.78B
Utile/perdita netta:
$3.68B
Rapporto P/E:
33.24
EPS:
5.1743
Flusso di cassa netto:
$5.29B
1 W Prestazione:
+6.23%
1M Prestazione:
-6.54%
6M Prestazione:
-24.36%
1 anno Prestazione:
-8.26%
Intervallo 1D:
$171.14
$174.95
Intervallo di 1 settimana:
$161.23
$174.95
Portata 52W:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Nome
Danaher Corp
Settore
Industria
Telefono
(202) 828-0850
Indirizzo
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, IDXX, WAT, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Goldman | Buy |
| 2025-12-02 | Iniziato | Morgan Stanley | Overweight |
| 2025-10-08 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| 2025-07-11 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-04-10 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-03-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-03-14 | Aggiornamento | Stifel | Hold → Buy |
| 2025-02-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-12-23 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-19 | Iniziato | Guggenheim | Buy |
| 2024-12-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-31 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-10-01 | Iniziato | Stephens | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-17 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-01-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-18 | Iniziato | HSBC Securities | Hold |
| 2023-12-13 | Ripresa | Wolfe Research | Peer Perform |
| 2023-12-07 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-05-01 | Iniziato | SVB Securities | Outperform |
| 2023-04-26 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-01-05 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-10-24 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-08-17 | Ripresa | Bernstein | Outperform |
| 2022-07-20 | Iniziato | UBS | Buy |
| 2022-06-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-01-11 | Iniziato | Bernstein | Outperform |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-10 | Reiterato | BofA Securities | Buy |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-23 | Reiterato | Goldman | Buy |
| 2021-07-16 | Iniziato | The Benchmark Company | Buy |
| 2021-04-07 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-03 | Ripresa | Barclays | Overweight |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-06-16 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-04-02 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-03-26 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-02-03 | Reiterato | Needham | Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-11-15 | Ripresa | Stifel | Hold |
| 2019-10-28 | Reiterato | Needham | Buy |
| 2019-10-14 | Ripresa | Credit Suisse | Outperform |
| 2019-07-19 | Reiterato | Needham | Buy |
| 2019-06-11 | Iniziato | Piper Jaffray | Neutral |
| 2019-05-30 | Iniziato | Wolfe Research | Outperform |
| 2019-04-17 | Reiterato | Needham | Buy |
| 2019-02-28 | Reiterato | Needham | Buy |
| 2019-02-25 | Aggiornamento | Janney | Neutral → Buy |
| 2019-01-03 | Iniziato | Needham | Buy |
| 2018-04-20 | Reiterato | Stifel | Buy |
Mostra tutto
Danaher Corp Borsa (DHR) Ultime notizie
Masimo earnings in focus as Danaher deal nears close - Investing.com
Danaher Corp. May Be the Smartest Bet in Biotech Right Now - AOL.com
Danaher Raises $3 Billion in Record Private-Placement Bond Sale - Bloomberg.com
Danaher Targets Carbon Capture And AI CMC To Shape Long Term Growth - Yahoo Finance
Danaher stock (US2358511028): diagnostics spin?off and Q1 earnings reshape the portfolio - AD HOC NEWS
Danaher Corp. stock (US2358511028): earnings beat keeps focus on life sciences recovery - AD HOC NEWS
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
Eagle Capital Management Bet on Danaher (DHR) for Its Mid-Teens EPS Growth - Yahoo Finance
Tissue Diagnostics Market to Reach USD 9.33 Bn by 2031 Driven by Expanding Precision Oncology Applications and Rising Adoption of Digital Pathology, Says Mordor Intelligence - GlobeNewswire Inc.
Danaher stock (US2358511028): spin-off, diagnostics focus and what the latest numbers reveal - AD HOC NEWS
Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead? - The Globe and Mail
Pall to Address a Key Decarbonization Challenge with Additively Manufactured Filtration - PR Newswire
Why The Narrative Around Danaher (DHR) Is Shifting With Bioprocess Recovery And Masimo Deal - Yahoo Finance
Danaher Corp. stock (US2358511028): insider awards highlight leadership confidence after guidance li - AD HOC NEWS
Danaher (NYSE: DHR) director Linda Filler receives stock and option grants - Stock Titan
Danaher (NYSE: DHR) SVP uses 281 shares for tax withholding, retains 8,291 - Stock Titan
[Form 4] DANAHER CORP /DE/ Insider Trading Activity - Stock Titan
Alan G. Spoon (DHR) awarded RSUs and stock options in new Danaher Form 4 - Stock Titan
Danaher (NYSE: DHR) director awarded RSUs and long-dated stock options - Stock Titan
Danaher (NYSE: DHR) director Teri List granted RSUs and stock options as board compensation - Stock Titan
Danaher (NYSE: DHR) awards director Zerhouni RSUs and stock options - Stock Titan
Danaher (NYSE: DHR) director granted RSUs and options in new award - Stock Titan
Danaher (DHR) director Charles Lamanna awarded RSUs and 1,699-share option - Stock Titan
Danaher shares climb as analysts turn more constructive after Q1 guidance lift - Quiver Quantitative
Danaher Corp. stock (US2358511028): restructuring after spin-off, new focus on life sciences - AD HOC NEWS
Northwestern Mutual Wealth Management Co. Acquires 186,584 Shares of Danaher Corporation $DHR - MarketBeat
Danaher stock (US2358511028): Q1 figures, dividend and analyst views in focus - AD HOC NEWS
Danaher stock (US2358511028): earnings momentum and dividend in focus for US investors - AD HOC NEWS
Masimo Corp stock (US5747951003): earnings, Danaher deal and what’s next for the medical-tech spec - AD HOC NEWS
Solid Q1 and Guidance Underlines Why Danaher Corporation (DHR) is one of Steve Cohen’s Large-Cap Stock Picks - Insider Monkey
Danaher Masimo Deal Shifts Growth Outlook And Investor Focus - Yahoo Finance
DoorDash Inc stock (US2358511028): Q1 2026 profit beat keeps growth story in focus - AD HOC NEWS
Danaher Corporation Trade Ideas — AQUISEU:DAPD - TradingView
Danaher Valuation Reset Highlights Recurring Revenues And Lean Operating Framework - Yahoo Finance
Danaher Seen on Path to Growth Reacceleration on Bioprocess Recovery, RBC Says - marketscreener.com
DHR Reinstated by RBC Capital -- Price Target Set at $200 - GuruFocus
Danaher Stock: Analyst Estimates & Ratings - Barchart.com
Danaher stock (US2358511028): spin-offs reshape the medtech group after latest quarterly numbers - AD HOC NEWS
Danaher (DHR) Receives Outperform Rating from RBC Capital with $200 Price Target - GuruFocus
RBC Capital assumes Danaher stock coverage with outperform rating - Investing.com UK
RBC Capital assumes Danaher stock coverage with outperform rating By Investing.com - Investing.com Nigeria
DoorDash Inc stock (US2358511028): investors weigh latest results and US food delivery outlook - AD HOC NEWS
Jim Cramer Discusses the Performance of Danaher and Its Peers - Insider Monkey
Danaher stock (US2358511028): Shares decline amid four-day losing streak - AD HOC NEWS
The Escalator: Rx&O, Danaher, Ruder Finn and more - Medical Marketing and Media
Transcript : Danaher Corporation Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 11 - marketscreener.com
Is Danaher Corporation (DHR) A Good Stock To Buy Now? - Yahoo Finance
Jim Cramer’s Take on 5 Stocks: Home Depot, Procter & Gamble, and Danaher - Insider Monkey
Cepheid Receives CE Marking Under IVDR for Xpert® GI Panel | Newswise - Newswise
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Danaher stock (US2358511028): Shares slide as institutional holdings shift - AD HOC NEWS
Danaher Corp Azioni (DHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
1.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):